肺疾患による二次性肺高血圧症に対する体外式人工呼吸の効果 by 佐藤 庸子
Effects of extrathoracic mechanical
ventilation on pulmonary hypertension
secondary to lung disease
著者名 佐藤 庸子
発行年 2016-11-18
URL http://doi.org/10.20780/00031922
1 3
J Anesth (2016) 30:663–670
DOI 10.1007/s00540-016-2172-7
ORIGINAL ARTICLE
Effects of extrathoracic mechanical ventilation on pulmonary 
hypertension secondary to lung disease
Yoko Sato1 · Noriyuki Saeki2 · Takuma Asakura2,3 · Kazutetsu Aoshiba4 · Toru Kotani1 
Received: 19 November 2014 / Accepted: 3 April 2016 / Published online: 18 April 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
limited to 1 h per day to prevent exhaustion. To assess res-
piratory and circulatory effects, percutaneous arterial oxy-
gen saturation (SpO2) was measured before and after each 
daily BCV session, and right heart catheter test [mean 
pulmonary artery pressure (mPAP), right atrium pres-
sure (RAP), pulmonary artery occlusion pressure (PAOP) 
and cardiac index (CI)] and serum N-terminal pro-brain 
natriuretic peptide (NT-proBNP) were measured before and 
after a series of BCV sessions.
Results SpO2 transiently improved after each BCV ses-
sion. After a series of BCV, mPAP decreased from 27.2 to 
22.4 mmHg (p = 0.0007). PAOP, CI and serum NT-proBNP 
levels decreased compared with baseline. No patients were 
treated with epoprostenol, iloprost, bosentan or sildenafil 
for PH.
Conclusion BCV may improve circulatory function in 
patients with PH caused by lung disease.
Keywords Biphasic cuirass ventilation · Pulmonary 
hypertension · Ventilator
Introduction
Structural and functional alterations of pulmonary vessels 
eventually lead to secondary pulmonary hypertension (PH) 
and cor pulmonale [1] in patients with chronic lung dis-
ease. These alterations are considered to be the end stage of 
chronic lung disease and the only effective treatment cur-
rently available involves supplemental oxygen, diuretics, 
digitalis and anticoagulants [1–3]. Recently, prostanoids, 
endothelin receptor antagonists and phosphodiesterase-5 
inhibitors have been tested as active treatments; however, 
their effectiveness remains controversial [4–7]. Guidelines 
published by the European Society of Cardiology/European 
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Purpose Biphasic cuirass ventilation (BCV) is a form of 
non-invasive extrathoracic positive and negative pressure 
mechanical ventilation. The present study was conducted to 
quantify our positive experience using BCV to dramatically 
improve gas exchange and cardiac function in patients with 
acute exacerbation of chronic respiratory failure and sec-
ondary pulmonary hypertension (PH).
Methods BCV was applied for 2 weeks in 17 patients 
with PH caused by lung disease. Ventilation sessions were 
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Respiratory Society do not recommend secondary PH as 
a target for treatment if pulmonary artery pressure (PAP) 
is <40 mmHg, citing a lack of available data regarding 
treatment safety and efficacy [8]. Long-term oxygen ther-
apy has been effective in improving the physical condition 
of patients with chronic obstructive pulmonary disease 
(COPD) and PAP <40 mmHg; however, use of long-term 
oxygen therapy does not contribute to prevention of COPD 
progression, including secondary PH [9].
Biphasic cuirass ventilation (BCV), a form of non-inva-
sive extrathoracic mechanical ventilation, is an advanced 
model of the iron lung. It consists of a cuirass and a pres-
sure source capable of providing both positive and negative 
pressure, which supports spontaneous breathing in a more 
physiological manner compared with positive pressure ven-
tilation. BCV remains in clinical use and has been shown to 
be as effective as non-invasive positive pressure ventilation 
for avoiding tracheal intubation in COPD patients [10].
Negative pressure ventilation (NPV) provided by BCV 
increases pulmonary blood flow after the Fontan opera-
tion [11] and improves oxygenation in newborn infants 
with persistent PH [12]. We have experienced dramatic 
improvements in gas exchange and cardiac function in 
adult patients with acute exacerbation of chronic respira-
tory failure and secondary PH when applying BCV [13]. 
Based on our experience and observations, we hypothe-
sized that BCV provides better oxygenation than baseline 
and reduces pulmonary vascular resistance (PVR) in PH 
caused by chronic lung disease. In the present study, we 
examined this hypothesis in patients undergoing BCV as a 
treatment for PH secondary to lung disease.
Methods
This observational study involved patients recruited from 
Tokyo Women’s Medical University Hospital and Synthe-
sis Shinkawabashi Hospital in Japan. The study was con-
ducted from April 2009 until April 2012 using a protocol 
approved by the ethics committee from each hospital. Writ-
ten informed consent was obtained from all patients.
PH was defined as mean pulmonary artery pressure 
(mPAP) >20 mmHg in accordance with guidelines from 
the Japanese Cardiac Society (2006). Steady-state PAP 
was measured by right heart catheterization. Exclusion cri-
teria were (1) PH caused by idiopathic pulmonary arterial 
hypertension, connective tissue disease, chronic thrombo-
embolism, portal hypertension, congenital heart disease, 
left heart disease, chronic hemolytic anemia, HIV infec-
tion or other unknown reason; (2) acute exacerbation of 
chronic lung disease; (3) unstable hemodynamics (such as 
acute heart failure, arrhythmia or myocardial ischemia); (4) 
infection of any organ; (5) pulmonary vasodilator medica-
tion, such as epoprostenol, iloprost, bosentan, or sildenafil; 
(6) failure in cuirass attachment due to a skin problem; and 
(7) otherwise judged by a physician as inappropriate for 
study inclusion.
Patient selection
Patients who regularly visited the hospital with dyspnea 
secondary to chronic lung disease were diagnosed with 
PH using ultrasonic echocardiography. First, right heart 
catheterization was performed and PH was definitively 
diagnosed during an approximate 2-week admission. 
Hemodynamics were measured at the same time (prior to 
starting a series of BCV sessions). BCV was performed 
on consecutive weekdays and a second right-heart cath-
eterization was performed just before hospital discharge 
to compare hemodynamics before and after BCV. Patient 
chest X-ray, blood analysis and pulmonary function tests 
were rechecked for comparison with results from the day 
of admission.
Right heart catheterization
Right heart catheterization was performed at the begin-
ning of an approximate 2-week admission. In each test, 
electrocardiograph and percutaneous arterial oxygen 
saturation (SpO2) were continuously monitored. Nonin-
vasive blood pressure was recorded every 5 min and arte-
rial blood gas was analyzed. Central venous pressure, 
right atrial pressure (RAP), PAP, pulmonary artery occlu-
sion pressure (PAOP) and cardiac index (CI) were meas-
ured using a thermodilution catheter with jugular venous 
access. mPAP and PVR were calculated using the formula: 
mPAP = diastolic PAP + (systolic PAP − diastolic PAP)/3, 
PVR = (mPAP − PAOP)/cardiac output.
BCV session
BCV was performed every weekday during admission 
using an RTX ventilator (United Hayek Medical, London, 
UK). To promote biphasic pressure with a time cycle, the 
control mode was used as an initial setting with a negative 
pressure from −15 to −25 cmH2O (synchronized to each 
patient’s inspiration) and a positive pressure from 3−10 
cmH2O (synchronized for expiration). BCV sessions were 
limited to 30–60 min/day to prevent exhaustion. Ventilatory 
rate and inspiratory:expiratory ratio were set and adjusted 
to synchronize with spontaneous breathing. To maintain 
stable conditions and record changes in oxygenation, SpO2 
was continuously monitored for several minutes prior to 
starting and after completing BCV.
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Blood samples
Venous blood samples were taken at admission and before 
discharge. Complete blood count, serum concentrations of 
N-terminal proB-type natriuretic peptide (NT-proBNP) and 
noradrenalin were measured for comparison.
Treatment of PH
Pharmacological treatments initiated prior to admission were 
not interrupted during the course of study. Long-term oxy-
gen therapy was maintained on one patient, with the flow 
dose of oxygen remaining unchanged. After the BCV study, 
all patients were asked the following three questions—Was 
the BCV comfortable? Did the BCV improve your dyspnea? 
Would you like to use the BCV at an outpatient clinic?
Statistical analysis
Statistical analysis was performed using JMP software, 
version 11.2.0 (SAS Institute, Cary, NC, USA). Normally 
distributed numerical data are expressed as mean and 
standard deviation (SD) values, whereas skewed data are 
expressed as median and interquartile range. Qualitative 
data are expressed as number and percentage. For normally 
distributed numerical data, Student’s t test was employed; 
whereas, for skewed numerical data, a Wilcoxon rank 
sum test was applied. SpO2 changes were analyzed using 
Kruskal–Wallis test. Two-sided P values <0.05 were con-
sidered statistically significant.
Results
Seventeen patients with steady-state PH caused by chronic 
lung disease were included in the study; Table 1 illus-
trates cohort characteristics. Table 2 indicates relevant 
characteristics of the two sub-classified patient groups. 
The restriction group included post-thoracoplasty for 
treatment of tuberculosis (n = 3), interstitial pneumonia 
(n = 1) or pulmonary asbestosis (n = 1). The COPD group 
included individuals at various stages of Global Initiative 
for Chronic Obstructive Lung Disease (GOLD; GOLD 2, 
n = 2; GOLD 3, n = 2; and GOLD 4, n = 7).
Of the 17 patients, 15 underwent catheterization twice 
and a series of BCV sessions during an approximate 
2-week admission. The remaining two patients underwent 
right heart catheterization first, but were discharged before 
BCV because of financial reasons or the Great East Japan 
Earthquake; however, they were readmitted to the hos-
pital for BCV. The number and final timing of BCV ses-
sions administered during an approximate 2-week admis-
sion (Table 3a, b) varied because of the availability of BCV 
equipment and catheter laboratory resources.
BCV improved oxygenation after each session; however, 
this effect was transient and SpO2 returned to baseline levels 
by the following day (Fig. 1a–c). Furthermore, after a series 
of BCV sessions, PaO2 and PaCO2 remained unchanged 
compared with baseline levels (Fig. 2). BCV signifi-
cantly decreased mPAP (27.2 ± 5.1 to 22.4 ± 4.9 mmHg, 
P = 0.0007), RAP (8.5 ± 4.8 to 4.7 ± 3.9 mmHg, 
P = 0.0044), PAOP (13.7 ± 5.6 to 8.8 ± 4.7 mmHg, 
P = 0.0041) and CI (2.7 ± 0.6 to 2.4 ± 0.5 l/min/m2, 
P = 0.0309), whereas PVR was unchanged (267.6 ± 114.5 
to 288.0 ± 100.5 dyne/s/m5, P = 0.67).
A significant decrease was observed in serum NT-
proBNP levels [136.5 (23.5–357.4) to 60.2 (39.4–190) pg/
ml, P = 0.0056, Fig. 3a], but not noradrenalin levels [411 
(291–784) to 389.5 (295–765.8) pg/ml, P = 0.599]. Mean 
blood pressure decreased significantly after each BCV ses-
sion (Table 5).
In subgroup analysis between COPD and restriction 
groups, mPAP decreased in both (COPD, P = 0.0167; 
restriction, P = 0.0481; Table 4). However, RAP 
(P = 0.003), PAOP (P = 0.007; Table 4) and serum NT-
proBNP levels decreased only in the COPD group [162 
(22.6–302.3) to 100.8 (43.9–131) pg/ml, P = 0.042; 
Fig. 3b]. CI and PVR did not change (Table 4); however, 
subgroup analysis indicated blood pressure, heart rate and 
noradrenalin remained unchanged (Table 5).
Table 1  Patient characteristics
BMI body mass index, COPD chronic obstructive pulmonary disease
Age, mean (±SD) years 70.1 ± 8.7
Male, n (%) 15 (88)
BMI, mean (±SD) kg/m2 19.1 ± 3.5
Disease, n (%), COPD 11 (64.7)
Post thoracoplasty 3 (17.6)
Others (old tuberculosis, asbestosis, interstitial  
pneumonia)
3 (17.6)
Table 2  Patient characteristics of the two groups
%VC vital capacity, FEV1.0 forced expiratory volume in one second
COPD Restriction
n 11 5
Age (years) 68.6 ± 9 69.4 ± 5.4
BMI 18.2 ± 3.8 20.2 ± 2.1
Weight (kg) 48.8 ± 12.8 51.4 ± 5.2
%VC 80.8 (64.8–97.6) 52.1 (47.7–58.5)
FEV1.0 (L) 0.78 (0.67–0.99) 1.09 (0.81–1.33)
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After the BCV study, all restriction group patients 
requested to take the device home because they felt com-
fortable and their dyspnea was almost completely attenu-
ated. Ten other patients indicated that their dyspnea 
improved but the trial was uncomfortable. Two COPD 
patients wanted to cease BCV because of discomfort, but 
cooperated for study completion.
Discussion
BCV was applied for 2 weeks in 17 patients with PH 
caused by lung disease. SpO2 after each daily BCV session 
improved transiently, but it was not enough to improve gas 
exchange even after a series of BCV sessions. After a series 
of BCV sessions, mPAP, RAP, PAOP and CI measured by 
right heart catheterization and serum NT-proBNP levels 
decreased compared with the baselines, whereas PVR did 
not. In subgroup analysis between COPD and restriction 
groups, only mPAP decreased in both groups.
It is obvious that hypoxemia and hypercapnia are major 
causes of PH; thus, long-term oxygen therapy or non-inva-
sive positive pressure ventilation has been used for patients 
with chronic lung diseases. A previous study reported long 
term non-invasive positive pressure ventilation improved 
gas exchange both in COPD and restriction groups, 
whereas mPAP only decreased within the restriction group 
[14]. Transient improvement of SpO2 by BCV possibly 
benefited patients in our study; however, these patients 
were stable and did not present with acute exacerbation of 
lung disease. Furthermore, BCV decreased mPAP in both 
the COPD and restriction group, suggesting it is unlikely 
that correction of hypoxemia and hypercapnia by BCV was 
the only cause of reduced mPAP.
There are two possible mechanisms by which BCV 
ameliorates PH. First, BCV may directly improve thoracic 
mobility. In the present study, ventilation measurements 
during BCV were not performed. However, many studies 
have shown tidal volume and minute volume increase with 
the use of NPV or BCV in healthy volunteers [15, 16], as 
well as in patients with chest wall diseases [17] and COPD 
[18]. Previous studies demonstrate that negative pressure 
relieves the diaphragm and other respiratory muscles in 
COPD patients [18, 19].
Extrathoracic negative pressure directly affects expan-
sion of the thoracic cage by stretching the diaphragm and 
intercostal muscles for inspiration (see Online Resource 1). 
Improvement of thoracic mobility increases ventilation vol-
umes and allows for comfortable respiration in restrictive 
lung disease patients. Indeed, all restriction group patients 
requested further BCV therapy after discharge. Extra-tho-
racic positive pressure during expiration assisted return to 
resting position and may assist in elastic recoil of the chest 
wall (see Online Resource 1).
Pressure swings caused by airflow limitation and reduc-
tion of the vascular bed have been shown to elevate PAP 
in COPD patients [1, 20]. Severe airflow limitation in 
COPD patients with normal left ventricular function results 
in superimposed pressure in both the left and right ventri-
cles caused by auto-positive end expiratory pressure. An 
increase in both intrathoracic pressure [1] and dynamic 
hyperinflation [21] has been shown to increase PAOP, 
which acts interdependently with RAP [22]. Grasso and 
colleagues reported that NPV provides more effective lung 
inflation volume uniformity during both inspiration and 
expiration compared with positive pressure ventilation in 
an acute lung injury model in rabbits [23]. NPV, when used 
for high-frequency ventilation, has been shown to lower 
intrathoracic negative pressure [24, 25]. Thus, if BCV 
decreases intrathoracic pressure, eventually extinguishes 
auto-positive end expiratory pressure and also provides 
uniform ventilation, it decreases PAOP as well as RAP. 
Because the stroke index parallels PAOP, BCV mitigates 
the workload of both ventricles, leading to a decrease of 
whole parameters in the right cardiopulmonary unit.
Second, BCV may decrease the work required for 
breathing by influencing interactions between respiration 
and circulation. CI decreased statistically, but data recov-
ered to normal ranges. BCV may decrease cardiac load to 
reduce excess work of breathing associated with chronic 
lung disease and decreased serum NT-proBNP. It is highly 
likely that mitigation of breathing workload normalizes CI. 
Furthermore, improvement in thoracic mobility by BCV, 
both inspiratory and expiratory support, correlates with 
decreased work of breathing.
We anticipated PVR would decrease during this study, 
but results from our series of BCV sessions indicated 
unchanged PVR in all cases and subgroup analyses. Whole 
parameters, including CI, significantly decreased in the 
right cardiopulmonary unit, i.e., data recovered to within 
normal ranges. In our study, BCV may reduce exercise 
Table 3  (a) Number of BCV sessions, (b) Final timing of BCV ses-
sion of the second catheterization
COPD Restriction
(a) Number of BCV sessions
 8 times 2 1
 9 1 1
 10 4 3
 11 3 0
 12 1 0
(b) Final timing of BCV session of the second catheterization
 1 day before 6 2
 On the morning 5 3
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load by positively impacting inefficient respiration within 
patients.
BCV is one type of NPV approach; positive pressure 
ventilation does not have a similar effect on pulmonary cir-
culation. Negative pressure ventilators using a whole body-
sized box are still used in Europe, but this type utilizes con-
tinuous external negative pressure regardless of inspiratory 
and expiratory phases of the respiratory cycle. In contrast, 
BCV used in our study affects only the thorax and sup-
ports both inspiration and expiration individually. Thus, 
its effects are different from those exerted by continuous 
NPV. We believe that the effects displayed in this study are 
unique to BCV.
NT-proBNP plays a pivotal role in predicting PH—a 
reduction of >15 % per year is associated with improved 
mortality [26, 27]. As NT-proBNP increases stress on the 
ventricular wall, a decrease in this protein confers after-
load reduction within the right ventricle and/or adaptation 
of ventricles to stress [28]. As the period of examination 
was limited in the present study, adaptation was unlikely; 
thus, afterload reduction represents the most probable 
explanation.
Fig. 1  Saturation of peripheral oxygen (SpO2) before and after daily 
biphasic cuirass ventilation (BCV) sessions. a SpO2 of total cases. 
b SpO2 of chronic obstructive pulmonary disease (COPD) group. c 
SpO2 of restriction group. Closed box pre-BCV; closed triangle post-
BCV; n patient number. BCV transiently improved oxygenation in 
total cases and COPD group. *P < 0.05 versus pre-BCV
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Other limitations of the current study include the small 
sample size, especially for the restriction group. Further-
more, this study was not designed as a control trial because 
of various limitations in controlling patient conditions. 
Ethical problems would have arisen if the control group 
had right heart catheterization performed twice during the 
study period without therapeutic intervention with BCV. 
Finally, as catheterization procedures within each facility 
could only be scheduled on certain days of the week, BCV 
sessions frequently had to be rescheduled. In general, BCV 
sessions were performed on weekdays because of insuf-
ficient availability of human resources at weekends. As 
implementation of BCV was negatively affected by week-
ends, holidays and unexpected human resource problems, 
the number and timing of BCV sessions consequently 
varied.
It is possible that resting in hospital without any work-
load is associated with the observed reduction of patient 
Fig. 2  Changes in partial pressure of oxygen (PaO2) (a) and partial 
pressure of carbon dioxide (PaCO2) (b) before and after a series of 
BCV sessions. Arterial blood gas was measured at the same time as 
right heart catheterization, and no statistically significant differences 
were found. Box represents interquartile range and horizontal line 
across the box represents median. Error bars represent minimum and 
maximum. COPD group, simple line box; restriction group, dot line 
box
Fig. 3  Changes in serum N-terminal proB-type natriuretic pep-
tide (NT-proBNP) before and after a series of BCV sessions. a NT-
proBNP decreased significantly after BCV in all cases (P < 0.05). b 
NT-proBNP significantly decreased in the COPD group but not in the 
restriction group. COPD group, simple line box; restriction group, dot 
line box. Box represents interquartile range and horizontal line across 
the box represents median. Error bars represent minimum and maxi-
mum. Dots represent outlier. *P < 0.05
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blood pressures. However, it is unlikely that bed rest for 
approximately 2 weeks solely underlies the significant 
decreases observed in mPAP, RAP, PAOP, CI, mean BP and 
NT-proBNP in patients presenting with chronic respiratory 
disease for decades. Furthermore, none of the patients had 
worked for several years, remaining at home most days 
because of respiratory failure.
Conclusion
A series of BCV sessions significantly decreased mPAP 
in this patient cohort. As improvement in oxygenation by 
BCV was transient, other factors—especially decreased 
cardiac overload—likely play a role. BCV may provide a 
promising approach for treating PH caused by chronic lung 
disease. However, additional studies are needed to define 
duration, frequency and long-term effects of BCV in a 
larger sample size. Further consideration of the influence of 
BCV on respiration and circulation is required, as well as 
determination of mechanisms underlying potential patient 
benefits.
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